Company profile
Specialist Ophthalmology Contract Research | MediNect Ophtho | Belfast, UK
MediNect Ophtho offers focused preclinical retinal disease research solutions for biotechs, globally. New improved models I Highly collaborative I in vivo I in vitro I retinal disease models I Ophthalmology CRO
Financial period: 1 Apr 2024 to 31 Mar 2025
Reference milestones and recent Companies House filing stream events.
Next confirmation statement due date
Next accounts due date
Last confirmation statement made up date
Last accounts made up date
Company registered at Companies House
1 May 2025 to 30 Apr 2026
MediNect Bioservices is advancing the frontiers of preclinical research in ophthalmology by expanding its capabilities to address critical unmet needs in retinal disease. Our main innovation is an in vivo model of subretinal fibrosis, a devastating end-stage phenotype of age-related macular degeneration (AMD) that leads to irreversible vision loss. Subret...
1 Oct 2022 to 30 Sep 2023
Diabetic Retinopathy (DR) and Age-related macular degeneration (AMD), termed retinal disease herein, are the leading cause of vision loss worldwide, affecting over 300 million people. Current treatment strategies for retinal disease are limited, with poor efficacy observed in late-stage clinical trials of promising drugs. This is attributed to poor precli...
